Skip to main content

News

Dual Cytokine Inhibition for RA

The notion of a single biologic targeting two cytokines is intriguing. ABT-122 is a new dual-variable domain immunoglobulin that neutralizes both TNF-α and IL-17A.

The Spirit of ACR 2016

All week I’ve attempted to catch the spirit of ACR and rheumatology in a picture or quote, but after attending ACR 2016 in Washington, DC, I found myself surrounded by examples.

ACR 2016 – Day 3 Highlights

Some big highlights from Tuesday at the 2016 ACR/ARHP annual meeting included the PRECISION trial, EXXELERATE trial and the new anti-IL-23 in psoriatic arthritis.

Celecoxib Shines and Naproxen Tanks in the PRECISION Study

The PRECISION trial was published this week in the NEJM, presented at the Cardiology meetings in New Orleans, and presented today by Dr. Daniel Solomon at the 2016 ACR annual meeting in Washington, D.C. (citation source http://buff.ly/2fUmoqO)

Diffuse Cutaneous Systemic Sclerosis: Results of the SCOT Trial

Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.

Guselkumab Efficacy and Tolerability in PsA/PsO

New treatment options for psoriatic arthritis continue to be explored at this year’s ACR/ARHP Annual Meeting in Washington, DC. Guselkumab (GUS) is a fully human monoclonal antibody against the p19 subunit of IL-23.  

Tocilizumab Infections Less in ACPA+ Patients

Tocilizumab is in the spotlight at this year’s ACR 2016 meeting but there is still much to learn, including more about its safety profile. In an abstract presented at today’s poster session (Abstract 2618), Morel, et al.

ACR 2016 – Day 2 Highlights

Big highlights from Monday included the Hench Lecture, plenary session abstracts and presentations on drug safety and cost efficacy in rheumatoid arthritis.

Maintenance of Remission in ANCA-vasculitis: MAINRITSAN study.

It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.

Herpes Zoster and Giant Cell Arteritis

The potential association of herpes zoster with giant cell arteritis (GCA) has been a debated topic and certainly has gotten some attention at ACR 2016 this year.

MACRA: Not Just an Acronym Inside an Acronym

Education on MACRA is the key to successful survival. The important take home points noted in Dr. Will Harvey’s lecture at ACR 2016 (session title: Holy MACRA! How to Survive and Thrive in the New Era of MACRA, MIPS, and APMs) are stated below.

ACR 2016 – Day 1 Highlights

The annual ACR meeting began last night with a number of famed rheumatologists being inducted as ACR Masters.
×